Novartis snaps up MS indication for Glaxo's Arzerra
- Arzerra (ofatumumab) is being studied for use in various diseases, including cancer and multiple sclerosis (MS). Novartis has already purchased rights to certain cancer indications for Arzerra.
- Arzerra is a fully human monoclonal antibody that targets the CD20 protein, leading to depletion of B cells. This mode of action has a therapeutic impact in MS.
- Previously, Novartis purchased the cancer indications for Arzerra.
The addition of Arzerra's MS indication makes sense given Novartis' focus on neuroscience, and MS in particular. Novartis' current portfolio includes Gilenya (fingolomid), Glatopa (a generic version of Teva's Copaxone---glatiramer acetate) and two investigational compounds, BAF312 and CJM112.
According to the deal's structure, GSK will receive $300 million upfront, and $200 million once phase III trials are started. In addition, GSK will be eligible to receive up to $534 million in milestone payments, as well as up to 12% overall of net sales of Arzerra related to autoimmune conditions.
- Pharma Times Novartis buys rights to GSK's Arzerra in MS